pdgf axitinib  (Cell Signaling Technology Inc)

Journal: JNCI Journal of the National Cancer Institute

Article Title: Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study

doi: 10.1093/jnci/djw133

Figure Lengend Snippet: Targeted agents in clinical hepatocellular carcinoma studies, grouped by biologic compartment

Article Snippet: We will briefly describe several forms of preclinical tests that are used in the study of HCC and suggest which might be most suitable for this purpose. table ft1 table-wrap mode="anchored" t5 Table 2. caption a7 Compartment Target Agents Tumor growth factors EGF Cetuximab * , erlotinib * , vandetanib * PDGF Axitinib, BIBF 1120, linifanib, MEDI-575, orantinib, preretinoin, pazopanib * , sorafenib * , sunitinib * IGF AVE 1642, BIIB 022, cixutumumab, linsitinib, MEDI-573 TGF LY2157299 HGF TAC-101 Cell signaling pathways PI3K/mTOR AZD 8055, CC-223, NVP-BEZ 235, salirasib, evorlimus * , sirolimus * , tacrolimus * MEK/ERK BAY 86-9766, isomalto oligosaccharide sulfate, PD 0325901, selumetinib JAK/STAT AZD 1480, OPB-31121 “Pro-apoptotic” Artemisinin, cantharidin analogues, fenretinide, genistein, melatonin, xanthohumol, XIAP antisense AEG 35156, fluvastatin * , simvastatin * HDAC Belinostat, panobinostat, resminostat, vorinostat * Tumor microenvironment VEGF Apatinib, axitinib, brivanib, cediranib, cabozantinib, foretinib, linifanib, nintedanib, orantinib, ramucirumab, vatalanib, bevacizumab * , pazopanib * , sorafenib * , sunitinib * , vandetanib * PDGF Axitinib, linifanib, nitedanib, orantinib, preretinoin, pazopanib * , sorafenib * , sunitinib * Other antiangiogenics AMG 386, bavituximab, PI-88, tetrathiomolybdate, lenalidomide * , thalidomide * Hypoxia Darinaparsin, TH-302 Open in a separate window *US Food and Drug Administration–approved.

Techniques: Protein-Protein interactions, Analogues